DCF divergence forces downgrade. Model: FV $47, P(>cur) 2.4%. Implied growth 20.8% vs GLP-1 headwind narrative. FDA Smart Basal clearance captured, CMS Stelo is upside. But DCF is too bearish to ignore. Reducing 7→6. Need catalyst to re-rate.
Citi raised PT →, buy rating. Analyst consensus .18. Healthcare sector (XLV) -5% from Iran war rotation — sector headwind not company-specific. CMS Stelo expansion not in 2026 guidance = upside optionality. Thesis intact but sector noise creates near-term pressure. Trimming from implied 8→7 to reflect sector headwind risk.
RAISING 7→8. FDA clearance of Dexcom Smart Basal (first CGM-integrated T2D basal insulin dosing optimizer) is thesis-accretive and new information. T2D is 10x the T1D market and historically under-served by CGM. This extends DXCM from a CGM company to a T2D decision-support platform. ATTD conference presentation this week reinforces momentum. CEO back, FY25 +16% revenue, FDA now expanding T2D use case. Raising conviction. Target , stop .
Fair Value Distribution — percentile bands
6.0% of simulations place fair value above current price
WHAT IS PRICED IN
Revenue-Based Reverse DCF
19.0%/yr
±4.6% · revenue growth to justify current price
FCF-Based Reverse DCF
11.5%/yr
±3.1% · FCF growth to justify current price
THE GAP
Market pricing margin expansion or capex normalization
KEY VALUE DRIVERS
Spearman correlation — what moves this valuation most
FDA just cleared Smart Basal — first CGM-integrated insulin dosing optimizer for type 2 diabetes, expanding TAM from 10M type 1 patients to 100M+ type 2. G7 sensor tech leads the market on accuracy and wear time. RSI 34 near oversold — technical setup for a bounce as ATTD conference catalyzes awareness.
Stock has been a persistent underperformer, struggling to hold gains despite positive catalysts. GLP-1 overhang remains — market fears Ozempic/Mounjaro reduce the diabetic population needing CGMs. Competitive pressure from Abbott's Libre mounting on price. Enhanced signal 2.26 is mid-pack, not compelling enough to warrant adding.
GLP-1 drugs proven to reduce CGM demand, Abbott Libre taking share below 50%, Smart Basal commercial launch delays
Updated Mar 11
FDA clearance for Smart Basal extends DXCM's TAM into type 2 diabetes basal insulin management, pairing CGM data with dosing guidance. Thesis-accretive: T2D is 10x the T1D market and historically unde...
Leadership stability confirmed with Sayer returning to Executive Chairman role. Presented at Raymond James conference. High IV in options near March 20 expiry - possible catalyst expected by market.
DXCM FY25 10-K: 16% rev growth to 4.66B, strong margin expansion, 2B liquidity. G7 15 Day/Stelo on track. Key risks: 2028 Medicare bidding cliff, FDA warning letter. Fair value 88-95 vs 73 current.
DXCM 10-K 2025: G7 15Day clinical leadership + Stelo OTC TAM expansion offset by 2028 Medicare competitive bidding risk and March 2025 FDA warning letter. Bull case: superior tech, ecosystem lock-in, ...